Our Vision

The Epsilon Group (TEG) is committed to improving the understanding of disease and disease management by providing simulation/modeling software and services. Our innovative software products enable novice-to-expert researchers to approach problems found in translational science toward greater understanding and improved modeling of the pharmacokinetics and pharmacodynamics of novel treatment strategies.

With advances in the understanding of the biological processes of health and disease, there has been considerable increase in the application of computer-based integrated systems modeling (i.e. the use of quantitative mathematics and statistics), in the study of how human physiological systems function. These models have become an important tool for translational research in silico experimentation allowing the examination of the cause and effect interplay of a “computerized” human response to the perturbation created by disease conditions and treatment.

The appropriate use of mathematical models offers many potential benefits. For early stage treatment development, models provide an approximate description of many complex, dynamic processes. As such, modeling, simulation and statistical analyses can be an essential tool throughout drug discovery and development, such as:

Biological Modeling

Modeling and simulating the biological systems to guide the selection of pathways and cell targets

Hypothesis Testing

Enabling hypotheses testing concerning the physiological and pathophysiological structure of interest and multifocal targets

Study Optimization

Examining and improving experimental study design and identifying patient populations

Dose Optimization

Determining dose formulation, dosing range, dose escalation and timing patterns

Additionally, these models allow parameter estimations (biochemical quantities) that are not accessible to direct measurement; provide greater insight into the drug-body interaction, reduce costly laboratory and clinical trials spending, increase efficiency in identifying and testing viable and non-viable candidate compounds, reduce phase II and III attrition, and ultimately save money, time and lives.

TEG offers several levels of computer modeling software programs and services that have been shown to improve disease management for laboratory researchers, healthcare providers and patients dealing with disease, particularly in the area of diabetes mellitus and its related diseases. Please see our T1DMS  and DMMS.R software and services offerings to learn how we can help you.

Scroll to Top